Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Immunocore Holdings Ltd (IMCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: IMCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 24.51% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.74B USD | Price to earnings Ratio - | 1Y Target Price 62.18 |
Price to earnings Ratio - | 1Y Target Price 62.18 | ||
Volume (30-day avg) 487200 | Beta 0.83 | 52 Weeks Range 23.15 - 41.54 | Updated Date 06/14/2025 |
52 Weeks Range 23.15 - 41.54 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.48% | Operating Margin (TTM) -3.85% |
Management Effectiveness
Return on Assets (TTM) -1.83% | Return on Equity (TTM) -5.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1339066560 | Price to Sales(TTM) 5.22 |
Enterprise Value 1339066560 | Price to Sales(TTM) 5.22 | ||
Enterprise Value to Revenue 4.01 | Enterprise Value to EBITDA -45.82 | Shares Outstanding 50233600 | Shares Floating 37423034 |
Shares Outstanding 50233600 | Shares Floating 37423034 | ||
Percent Insiders 5.18 | Percent Institutions 97.38 |
Analyst Ratings
Rating 4.12 | Target Price 62.18 | Buy 5 | Strong Buy 8 |
Buy 5 | Strong Buy 8 | ||
Hold 3 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Immunocore Holdings Ltd
Company Overview
History and Background
Immunocore Holdings Ltd was founded in 1999 as a spin-out from the University of Oxford. It is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAC molecules. They focus on treating cancer, infectious diseases and autoimmune diseases.
Core Business Areas
- Oncology: Development and commercialization of ImmTAC molecules for the treatment of various cancers.
- Infectious Diseases: Research and development of ImmTAC molecules for infectious disease targets.
- Autoimmune Diseases: Research and development of ImmTAC molecules for autoimmune diseases.
Leadership and Structure
The company is led by Bahija Jallal, Ph.D., Chief Executive Officer. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Kimmtrak (tebentafusp): Kimmtrak is Immunocore's first commercial product, approved for the treatment of unresectable or metastatic uveal melanoma. This is a rare eye cancer. While precise market share data is dynamic, Kimmtrak enjoys a dominant position due to it being the first approved therapy for this indication. Competitors: No direct competitors with the same mechanism of action.
- Pipeline Programs: Immunocore has a pipeline of ImmTAC molecules in clinical development for other cancer types and infectious diseases. Revenue generated from these programs is currently limited to collaboration agreements.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investment in cancer immunotherapy. The demand for innovative cancer treatments is high, driving research and development efforts.
Positioning
Immunocore is positioned as a leader in TCR bispecific immunotherapy. Its ImmTAC technology provides a novel approach to target intracellular cancer antigens. Immunocore has a competitive advantage with Kimmtrak being the only approved treatment for metastatic uveal melanoma.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is substantial, estimated to be hundreds of billions of dollars. Immunocore's current focus on uveal melanoma is a smaller market, but the potential for its ImmTAC platform to address larger cancer markets positions it well for future growth.
Upturn SWOT Analysis
Strengths
- First-in-class TCR bispecific immunotherapy platform (ImmTAC)
- Approved product (Kimmtrak) with demonstrated efficacy
- Strong intellectual property portfolio
- Experienced leadership team
- Potential to address a wide range of cancers and other diseases
Weaknesses
- Reliance on a single approved product (Kimmtrak)
- High cash burn rate typical of biotech companies
- Clinical trial risks associated with pipeline programs
- Manufacturing complexities of ImmTAC molecules
- Competition from established immuno-oncology therapies
Opportunities
- Expansion of Kimmtrak into earlier lines of uveal melanoma treatment
- Development of ImmTAC molecules for other cancer types with high unmet need
- Partnerships with pharmaceutical companies to accelerate development
- Expansion of the ImmTAC platform into infectious diseases and autoimmune diseases
- Advancements in manufacturing processes to reduce costs
Threats
- Clinical trial failures of pipeline programs
- Competition from emerging immunotherapy technologies
- Regulatory hurdles and delays
- Pricing pressures on cancer therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- NVS
Competitive Landscape
Immunocore's ImmTAC technology provides a unique approach to cancer immunotherapy, targeting intracellular antigens. While it faces competition from established immuno-oncology therapies (e.g., checkpoint inhibitors), its novel mechanism of action and the success of Kimmtrak give it a competitive advantage. Further success relies on the development of its pipeline.
Major Acquisitions
No significant acquisition data available
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: No significant acquisition data available
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by the launch and uptake of Kimmtrak. Future growth will depend on pipeline development and expansion into new indications.
Future Projections: Future growth will depend on pipeline development and expansion into new indications. Analyst estimates are not generated here.
Recent Initiatives: Recent initiatives include expanding the clinical development program for Kimmtrak, advancing pipeline programs, and establishing partnerships to accelerate research and development.
Summary
Immunocore is a promising biotech company with a first-in-class TCR bispecific immunotherapy platform. Kimmtrak's success validates the platform, but the company is still reliant on a single product. Pipeline development is critical for future growth, while navigating clinical trial risks and competition from established therapies remains key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Immunocore Holdings Ltd. Investor Relations
- SEC Filings (10-K, 10-Q)
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunocore Holdings Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | CEO & Executive Director Dr. Bahija Jallal Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 493 | Website https://www.immunocore.com |
Full time employees 493 | Website https://www.immunocore.com | ||
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.